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Abstract
In the early phases of the SARS coronavirus type 2 (SARS- CoV-2) pandemic, testing focused on individuals fitting a strict case 
definition involving a limited set of symptoms together with an identified epidemiological risk, such as contact with an infected 
individual or travel to a high- risk area. To assess whether this impaired our ability to detect and control early introductions of 
the virus into the UK, we PCR- tested archival specimens collected on admission to a large UK teaching hospital who retrospec-
tively were identified as having a clinical presentation compatible with COVID-19. In addition, we screened available archival 
specimens submitted for respiratory virus diagnosis, and dating back to early January 2020, for the presence of SARS- CoV-2 
RNA. Our data provides evidence for widespread community circulation of SARS- CoV-2 in early February 2020 and into March 
that was undetected at the time due to restrictive case definitions informing testing policy. Genome sequence data showed that 
many of these early cases were infected with a distinct lineage of the virus. Sequences obtained from the first officially recorded 
case in Nottinghamshire - a traveller returning from Daegu, South Korea – also clustered with these early UK sequences sug-
gesting acquisition of the virus occurred in the UK and not Daegu. Analysis of a larger sample of sequences obtained in the 
Nottinghamshire area revealed multiple viral introductions, mainly in late February and through March. These data highlight the 
importance of timely and extensive community testing to prevent future widespread transmission of the virus.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-
 CoV-2) is a novel zoonotic virus, first identified in the city of 
Wuhan in the Chinese province of Hubei, following a cluster 
of patients presenting with severe pneumonia [1]. Since this 
first detection in December 2019, SARS- CoV-2 has rapidly 
spread across the globe and, as of 30 March 2021, there have a 
been a total of 127349248 confirmed cases globally, resulting in 
2787593 deaths [2]. Within the UK, there have been 4337700 
lab- confirmed cases and 126615 deaths, as of 30 March 2021 [2].
Infection with SARS- CoV-2 can lead to the development 
of coronavirus disease 2019 (COVID-19), characterised 
by fever, persistent cough, fatigue and shortness of breath 
[3, 4]. In severe cases, this can progress into acute respira-
tory distress syndrome (ARDS), which often requires artifi-
cial ventilation, and even multi- organ failure and death [5]. 
Despite these serious potential sequalae, many cases present 
asymptomatically or with only mild disease. Asymptomatic 
and pre- symptomatic carriage of SARS- CoV-2 is now well 
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[8–10], which is thought to be related to high levels of viral 
shedding in the upper respiratory tract during the early stages 
of infection [11]. Due to the difficulty in identifying infected 
asymptomatic or pre- symptomatic individuals, SARS- CoV-2 
has been able to rapidly spread, particularly in healthcare and 
age care environments [12].
Initial SARS- CoV-2 RT- PCR testing in the UK was offered via 
referral to Public Health England (PHE) national and regional 
diagnostic laboratories, and required strict epidemiological 
and clinical criteria to be met, specifically a recent travel 
history to Hubei province or contact with a known case and 
one or more of fever, shortness of breath or new and persistent 
dry cough. These case definitions were revised on several occa-
sions to include travel to mainland China and several other 
Asian countries initially (7 February), then expanded further 
to include Iran and northern Italy (25 February) before finally 
being removed as essential criteria for diagnostic testing on 12 
March [13]. Importantly, a case definition that relied heavily 
on travel history or exposure to a known infected individual 
likely resulted in undetected cases and transmission in 
both healthcare and community settings. A broadening of 
epidemiological criteria in COVID-19 case definitions was 
associated with an increased proportion of COVID-19 cases 
being identified [14]. Furthermore, as SARS- CoV-2 testing 
was initially only available via PHE laboratories, and testing 
within NHS laboratories was not rolled out until March 2020, 
this further restricted the capacity to detect early cases and 
transmission events.
The first confirmed SARS- CoV-2 case detected in the United 
Kingdom travelled from Hubei province on 23 January 2020 
and became symptomatic on 26 January. This patient then 
transmitted the virus to a household contact, who also became 
symptomatic 2 days later [15]. The third diagnosed case was 
in a traveller returning from Singapore on 6 February; this 
patient had stopped in France where they infected seven 
others, before travelling to and seeding several infections in 
the UK [16]. Retrospective phylogenetic modelling based on 
genome and associated metadata has conservatively estimated 
a minimum of 1356 independent introductions of the virus 
into the UK, primarily from travellers originating in Spain, 
France or Italy during mid- March [17], although definitive 
proof of early introduction of SARS- CoV-2 into the UK 
before widespread testing has been lacking. There have been 
several reports of early circulation of SARS- CoV-2 in these 
mainland European countries [18–21], however, a World 
Health Organization (WHO) report concluded that these 
reports remain unconfirmed due in part to a lack of sequence 
data [22]. Similar cases of SARS- CoV-2 have been reported in 
the UK [23], but the authenticity of these reports have again 
not been supported with any sequence data.
To better understand the prevalence and emergence of 
SARS- CoV-2 in the UK before the broadening of case defi-
nition criteria and wider testing, retrospective PCR testing 
of archived diagnostic specimens submitted for respira-
tory virus screening, review of case histories to identify 
individuals with symptoms compatible with SARS- CoV-2 
infection. To investigate how any undetected cases of 
SARS- CoV-2 infection may have influenced the genomic 
epidemiology within Nottingham in the months following 
the rollout of localised testing, we analysed SARS- CoV-2 
genomes sequenced from Nottingham patients between 
March and June 2020. This study was conducted in a large 
teaching hospital located in Nottingham and representative 
of provincial cities throughout the UK. We describe the 
detection of SARS- CoV-2 from eight patients admitted to 
hospital with severe respiratory distress who were not tested 
at the time because they had no travel history or contact 
with someone infected and therefore did not meet the case 
definition applied at the time. Sequence analysis of these 
early cases showed that they belonged to a distinct B- lineage 
of SARS- CoV-2 which dominated the early phases of the 
local outbreak. Analysis of further sequences, collected 
as part of the COG- UK initiative [24] from patients who 
tested positive after the rollout of local testing, highlighted 
extensive introductions of the virus into the region.
METHODS
Sample collection
A total of 1660 respiratory specimens (throat swabs, nose 
swabs, nasopharyngeal aspirates, bronchoalveolar lavages 
and endotracheal tube secretions) from 1378 patients were 
collected between 2 January and 11 March 2020 for routine 
diagnostic investigation [25] for which surplus total nucleic 
acid was available. To facilitate rapid testing, we created 169 
pools each containing up to 10 samples, which were then 
subjected to SARS- CoV-2- specific PCR.
RT-PCR screening and high-throughput sequence 
analysis
cDNA was synthesised from each of the nucleic acid pools 
using RNA to cDNA EcoDry (Random Hexamers) (Takara 
Bio Europe, Saint- Germain- en- Laye, France). Due to the 
national shortage of qPCR testing reagents and equipment at 
the time of this study, the cDNA was initially screened with 
an in- house PCR assay targeting the RNA- dependent RNA 
polymerase (RdRp) gene region of SARS- CoV-2, producing 
an 186 bp amplicon. Positive samples were then confirmed 
using a larger 366 bp amplicon assay, also targeting the 
RdRp. All positive samples were further confirmed by both 
Sanger and whole genome sequencing (WGS) and multiple 
negative controls were included in each run. For both assays, 
5 µl of cDNA was added to PCR reactions containing 5 µl 
of 10× PCR buffer, 0.25 µl of HotStarTaq DNA Polymerase 
(QIAGEN, Hilden, Germany), 2 µl each of both forward and 
reverse primers (10 pmol µl−1), 2 µl dNTPs (10 mM) (Sigma- 
Aldrich, St Louis, USA) and 33.75 µl of DEPC- treated water. 
Cycling conditions were 95 °C for 15 min, 55 cycles of 95 °C, 
58 and 72 °C for 20 s each, followed by a final extension of 
72 °C for 30 s. The primer sequences for the initial 186 bp 
assay was qCOV19f: 5′- CAATAGCCGCCACTAGAGGA 
and qCOV19r: 5′- GAGCAAGAACAAGTGAGGCC. 
The sequences for the larger assays were COV19_Cf: 
3
Chappell et al., Journal of General Virology 2021;102:001595
5′- CGCCACTAGAGGAGCTACTG and COV19_Cr: 
5′- GCCGTGACAGCTTGACAAAT.
Positive pools were de- multiplexed and the individual 
nucleic acid extracts were subject to the same methodology 
as the pooled samples. WGS was achieved using the ARTIC 
amplicon sequencing protocol [26], the complete method-
ology is available in the supplementary information.
Following the implementation of localised NUH SARS-
 CoV-2 testing using the RealStar SARS- CoV-2 RT- PCR 
Kit (Altona, Hamburg, Germany), positive samples were 
routinely subject to WGS. Selection was based on the daily 
laboratory capacity; when sequencing capacity exceeded 
sample number, sequencing was attempted from all positive 
samples with a diagnostic Ct value of 30 or under for one or 
both gene targets. Where the number of samples exceeded 
the daily capacity, samples were selected in numerical order 
to fill capacity, but duplicated ward sources were omitted to 
increase breadth of sampling.
Phylogenetic analysis
In total, 28 124 SARS- CoV-2 whole genomes with >95 % 
coverage were downloaded from GISAID on 10 June 2020. The 
processing of the genomes was performed with the Geneious 
Prime 2019.0.4 software. The genomes were sub- divided based 
on their lineage as indicated by the Pangolin tool [27]. For each 
lineage, the sequences were aligned and the 5′ and 3′ ends were 
trimmed. Maximum likelihood phylogenetic trees were gener-
ated for multiple lineages (B.1, B.1.1, B.1.1.1, B.1.p11, B.1.5, 
B.1.34, B.1.36, B.2, B.2.1, B.2.2, B.2.5, B.2.6, B.3, B.6, B.9, B.10, 
B.15) using IQ- TREE2 [28] employing the GTR+F+R3 model 
of nucleotide substitution as suggested by the software’s model 
finder, with 1000 SH- like approximate likelihood ratio test (SH- 
aLRT) [29]. Each tree was rooted using the early Wuhan virus 
hCoV-19/Wuhan/WH04/2020|EPI_ISL_406801|2020-01-05 
that was sampled in January 2020.
RESULTS
Clinical diagnosis of SARS-CoV-2
Prior to the rollout of localised SARS- CoV-2 testing on 12 
March 2020, nine cases (denoted Patients 9–17) matching 
the clinical and epidemiological contemporary case defini-
tions were identified and referred to PHE for testing (Table 1). 
Complete sequence data was available for one patient (Patient 
9), a traveller returning from South Korea, tested on 28 
February 2020.
A review of case histories revealed an additional five individuals 
whose symptoms were compatible with COVID-19 but who 
were not tested as they did not meet the epidemiological criteria 
of the contemporary case definition (Patients 4–8). As these 
were suspected to have SARS- CoV-2 infection, their respiratory 
samples were included in the verification of a local SARS- CoV-2 
PCR test within the Nottingham diagnostic virology labora-
tory, and subsequently referred to PHE for confirmatory testing. 
These patients were all males over the age of 50 whose samples 
were collected between 2 and 12 March. Complete virus genome 
sequences were obtained from all five patients: three were clas-
sified as lineage B (Patients 4–6), one as lineage B.2.2 (Patient 
7) and one as lineage B.2.5 (Patient 8).
Retrospective detection of SARS-CoV-2 in residual 
diagnostic material
Residual diagnostic material collected prior to 11 March, and 
not subjected to the SARS- CoV-2 testing described above, was 
retrospectively screened for SARS- CoV-2. The majority of 
these were throat swabs or nasopharyngeal aspirates, with only 
a small proportion of nasal swabs, sputum or other samples (Fig. 
S1a, available in the online version of this article). The patient 
demographics indicated a slightly higher inclusion of males than 
females (Fig. S1b). The proportion of children under the age of 
ten were also higher than other ages (Fig. S1c). All samples had 
originally been sent to the diagnostic virology laboratory for 
respiratory virus testing. Overall, 41 % of the samples contained 
at least one respiratory virus, with rhinovirus being the most 
frequently detected, followed by respiratory syncytial virus and 
human metapneumovirus (Fig. S1d). Non- SARS- CoV-2 coro-
naviruses were detected in 4.16 % of samples. An average of 170 
samples per week were collected throughout January, February 
and the first week of March, peaking at 234 samples collected 
between 2 and 8 March 2020 (Fig. S1e).
Of the 1660 samples tested, three SARS- CoV-2 positive samples 
were identified through retrospective PCR screening, each from 
a separate pool. These positive samples were collected from 
patients on 21 February (Patient 1), 2 March (Patient 2) and 
8 March (Patient 3). All three samples were throat swabs and 
there were no detectable co- infections with other respiratory 
viruses. Patient 1 is the earliest known detection of SARS-
 CoV-2 in Nottingham, collected 1 week before the previous 
earliest known positive meeting the contemporary case criteria 
(Table 1). This patient was a 75- year- old female, admitted to 
hospital following a fall and suffering from respiratory failure. 
Her condition worsened, requiring ventilation and the patient 
ultimately developed multi- organ failure and died on 3 March. 
No recent travel history or contact with a recently returned 
traveller was identified during care such that the PHE- defined 
case definition for SARS- CoV-2 testing at the time was not met. 
Patient 2 was a 64- year- old male being treated for a suspected 
liver abscess, presenting with repeated fevers, crackles were 
noted on lung auscultation but there were no abnormalities 
on chest X- ray. Patient 3 was a 66- year- old male admitted to 
hospital with a sore throat and symptoms of Guillain- Barre 
syndrome, with mild abnormalities also noted on a chest X- ray. 
Both Patients 2 and 3 recovered from their infections.
The complete SARS- CoV-2 genome was sequenced from all 
three samples; all were classified as lineage B.
Prevalence of SARS-CoV-2 lineages in Nottingham 
UK following the rollout of localised testing
A total of 1405 patients tested positive for SARS- CoV-2 
between 12 March and 2 June. The total number of positives 
detected per day peaked on 8 April before gradually declining 
from 22 April onwards (Fig. 1).
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SARS- CoV-2 positive samples were randomly selected for 
whole- genome sequencing: of these, 679 were successfully 
sequenced and classified into lineages. A total of 23 line-
ages were detected, with lineages B, B.1, B.1.1, B.1.1.1 and 
B.1.p11 the most frequent (Fig. 2a). Lineages B.1, B.11 and 
B were also the three most prevalent lineages globally (Fig. 
S2). Between 2 March and 3 June 2020, lineages B, B.1.1.1, 
B.1.1.9, B.1.8, B.1.p11, B.15, B.1.34, B.2.2, B.2.6 and B.6 
were proportionally more prevalent in Nottingham than 
the rest of the UK. Additionally, over 20 % of lineage B.1.1.9, 
B.1.8, B.1.34 and B.6 UK sequences were generated from 
specimens submitted to Nottingham diagnostic laborato-
ries for testing (Fig. 2b). The diversity of lineages detected 
each week varied over time. Diversity was greatest between 
week 12 and 15 (16 March to 12 April) and peaked in week 
13, during which 19 lineages were detected. The frequency 
of lineages B.1.1 and B.1.1.1 increased over time, while the 
other common lineages (B.1 and B.1.p11) decreased in 
frequency. The three lineages detected prior to the rollout 
of localised screening - B, B.2.2 and B.2.5 - all decreased in 
frequency; B.2.2 was last detected in week 17, B.2.5 in week 
13 and B in week 21 (Fig. 3). Fourteen lineages had not been 
detected in the month prior to 2 June, six of which had not 
been detected elsewhere in the UK for over a month. Only 
five lineages were detected in the final week of this study 
(Fig. S3).
Genomic epidemiology of SARS-CoV-2 in 
Nottingham
The majority of sequences obtained from patients during 
the retrospective ‘look- back’ analysis of archival respiratory 
samples were assigned to lineage B using the Pangolin tool. 
These sequences, together with other lineage B sequences 
sampled in Nottingham (following the introduction of 
localised screening), the UK and worldwide were then 
combined and subjected to phylogenetic analysis.
The resulting phylogeny shows that most lineage B 
Nottingham- derived sequences form a distinct clade 
within the B- lineage with strong statistical support (Figs 4 
and S3). Sequences collected from other regions in the 
UK (Sheffield, Cambridge and Exeter) and internation-
ally (Iceland, Portugal, USA) were also interspersed 
throughout this clade, suggesting an epidemiological 
connection to those infections in Nottingham. The 
sequence of Patient 1, which was derived from a specimen 
collected on 21 February, indicates that this individual was 
part of a transmission chain following the early introduc-
tion of this virus strain into the region. Importantly, this 
sequence clustered with, and predates what was previously 
thought to be the first case of SARS- CoV-2 infection, 
which was identified in a traveller returning from South 
Korea (Patient 9, Table 1).
The retrospectively detected B.2.2 sequence (Patient 7) 
forms a distinct clade with three other Nottingham- derived 
sequences detected in later weeks (Fig. S4g), suggesting an 
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Phylogenetic analysis of the remaining Nottingham- derived 
sequences was performed to determine the number of poten-
tial introductions of virus into the Nottingham area in the 
initial stages of the outbreak.
Lineages B.1.5, B.1.36, B.2.6, B.6, B.9 and B.15 were repre-
sented by a single sequence, each indicating a unique 
regional introduction of virus (Fig. S4a–f). Several 
Nottingham- derived sequences clustered together with 
sequences representing lineages B.1.34 and B.2.2, again most 
likely following a single introduction (Fig. S4b, g). Analysis 
of lineages B.1.1.1, B.1.P11, B.2.5 and B.3 shows that each 
lineage was independently introduced into Nottingham on 
at least two occasions (Fig. S4h–k), whilst lineages B.1.1, 
B.2 and B.2.1 appear to have been introduced at least three 
times (Fig 4l–n) and lineage B.1 appears to have been 
introduced on several occasions (Fig. S4o). Poor branch 
support in several of these phylogenies, lineage B.1 in 
particular, precludes the accurate determination of number 
of introductions, and possibly represents an underestimate 
of the number of unique introductions. On many occasions, 
Nottingham sequences clustered with sequences from other 
UK cities and/or other countries, indicating transmission 
of the virus via travelling, as well as the potential origins 
and/or destination of the transmission chains. Interestingly, 
in lineages B, B.1.1, B.1.1.1, B.1.p11, B.1.34, B.2 and B.2.2, 
small clusters of Nottingham sequences with high SH- aLRT 
support were observed (data not shown), suggestive of local 
community transmission chains of the virus.
DISCUSSION
The complete genome sequencing of SARS- CoV-2 combined 
with retrospective clinical and molecular evaluation has facili-
tated analysis of the introduction and subsequent prevalence 
of multiple lineages of the virus into Nottinghamshire in the 
East Midlands region of the UK. Our study reveals multiple 
community- acquired cases of SARS- CoV-2 lineage B viruses 
presenting at a regional healthcare centre, but failing to 
meet contemporary case criteria for testing in a diagnostic 
system with restricted capability and up to 1 month before 
the government imposed countrywide lockdown measures.
Patient 1 in this study is, to the best of our knowledge, the 
earliest described community- acquired case of SARS- CoV-2 
in the UK to be confirmed with viral sequence data, admitted 
to hospital care on 21 February 2020, and was also the first 
UK COVID-19 death, preceding the earliest known death 
by 2 days [30]. A median incubation period estimate of 
COVID-19 of 5.1 days (4.5–5.8) from infection to the pres-
entation of initial symptoms [31], in addition to the week 
prior to hospitalisation when the patient was also sympto-
matic, suggests that infection could have taken place as early 
as 9 February. This patient had no history of either travel 
or contact with travellers and so infection must therefore 
have occurred locally, suggesting an active wider network 
of community transmission than previously suspected. The 
first PHE- confirmed case of SARS- CoV-2 in Nottinghamshire 
meeting contemporary clinical testing criteria, Patient 9, was 
Fig. 1. Number of new SARS- CoV-2 cases detected in Nottingham University Hospitals patients per day, from the rollout of localised 
testing on 12 March until 2 June 2020.
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Fig. 2. Proportion of SARS- CoV-2 lineages detected between 21 February and 2 June 2020 in Nottingham, compared with the prevalence 
of the same lineages in the rest of the UK and elsewhere in the world during the same time period (a). The total count of these lineages 
is also shown as a percentage of the total count of the same lineages detected in the rest of the UK and world (b).
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sampled 1 week after Patient 1. This patient had recently 
travelled to South Korea, but their associated viral sequence 
belonged to the same clade of lineage B as Patient 1, which 
has been infrequently observed in global data sets. The patient 
developed a fever 5 days after returning to Nottingham, which 
is consistent with both acquisition in South Korea and local 
acquisition in the UK before or after international travel [31]. 
Locally acquired infection in Nottingham is probably the 
Fig. 3. Frequency of SARS- CoV-2 lineages detected in Nottingham between 21 February and 2 June 2020, per week, as total count (a) 
and as a proportion of the total number (b).
9
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most likely scenario, and certainly the most parsimonious 
explanation, given our evidence that this viral lineage was 
already circulating in the Nottingham area. This highlights 
the utility of next- generation sequencing and phylogenetic 
analysis in delineating the epidemiology of virus outbreaks.
Whilst initially common, the proportion of lineage B in 
Nottinghamshire fell sharply as the pandemic continued. At 
the time of writing, lineage B was last detected on 18 May in 
Nottingham and using the same nomenclature proposal in 
which lineages were defined, lineages are classed as ‘unob-
served’ after a month of not being detected [32].
The frequency of SARS- CoV-2 detection and lineage diver-
sity in Nottingham began to increase during mid- March 
and peaked during late March/early April. This is consistent 
with the findings of Pybus et al. [17], where the frequency of 
TMRCAs (Time of the most recent common ancestor), and 
therefore transmissions, in the UK peaks during late March. 
Some virus lineages appeared to have been introduced on 
multiple occasions and were transmitted widely, whereas 
others had fewer introductions and/or were associated 
with limited onward spread. Despite the unprecedented 
national and global effort, only a fraction of SARS- CoV-2 
infected individuals were diagnosed and sequenced, with 
further loss of sequence information due to a high- quality 
threshold, such that many novel introductions are likely to 
be undetected. The complete genome sequence data sets 
from which the phylogenetic analyses were derived are 
heavily biassed towards UK samples, due to unevenness 
Fig. 4. Phylogenetic relationships of SARS- CoV-2 sequences from lineage B based on their entire genome (29412nt). This is an extraction 
of a sub- tree that contains most of the lineage B sequences detected in Nottingham, including those identified during retrospective PCR 
testing. The earliest known sequence is shown in green, other sequences identified in patients during the retrospective analysis are 
shown in purple, sequences obtained from the first confirmed local case (a traveller returning from South Korea) are shown in blue 
and sequences obtained from other local patients identified after introduction of wide- screen testing are shown in red. For clarity some 
branches have been collapsed. Where a branch has been collapsed the geographical locations of where the sequences were obtained 
are shown at the tip, and the number of individual sequences represented is shown in parentheses. The tree was rooted on a Wuhan 
sequence sampled on 2020-01-05. Reference sequences are indicated by their GISAID accession numbers. Branch lengths are drawn 
to a scale of nucleotide substitutions per site. Numbers above individual branches indicate SH- aLRT bootstrap support. The complete, 
unedited lineage B phylogenetic tree is presented in Fig. S4.
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in global sequencing activity: by late April 2020, 53% of 
available genomes were sampled in the UK [33], despite 
accounting for only 3.4 % of reported cases [34]. This imbal-
ance will hinder inferences about the definitive sources of 
introduction to the UK, but conversely has allowed greater 
insight into subsequent national SARS- CoV-2 transmission 
within the UK and onwards to other destinations.
It is likely that the true prevalence of the virus within the 
local study setting and indeed the wider UK during the time-
frame of this study was much higher than we have reported 
here, particularly from early- February onwards, as our study 
was limited to symptomatic individuals requiring secondary 
medical care. Asymptomatically infected individuals, along with 
those presenting with mild or paucisymptomatic infection, are 
likely to comprise a significant proportion of the total number of 
infections. Prevalence of asymptomatic infections in representa-
tive American and Icelandic populations is high: between 40 
and 45 % of total infections [35], and as high as 87.5 % in younger 
cohorts [36]. Early epidemiological modelling predicted that for 
every hospitalised COVID-19 case in the UK, there may have 
been a further 120–124 infected individuals [37], whilst 89 and 
86 % of infections US and China, respectively, were undetected 
during the early months of the pandemic [38], supporting the 
hypothesis of a potentially significant incidence of undetected 
infection within the wider community.
Although a large cohort of surplus diagnostic material dating 
back to January 2020 was screened, it is possible that further 
SARS- CoV-2 positives within remain undetected. The pooling 
of respiratory samples, for example, may have contributed to 
a decrease in the detection rate. However, we consider this 
unlikely as similar pooling of samples has been shown to result 
in only a minor increase in reported Ct- values [39]. Also, the 
retrospective screening of surplus diagnostic material only 
captures respiratory samples taken from a specific subgroup 
of patients: those admitted to hospital predominantly with a 
suspected respiratory infection. Further false negatives within 
our cohort may have also arisen as our retrospective assay 
was not fully evaluated for clinical use and the broad clinical 
manifestation of COVID-19 was still emerging at the time of 
investigation.
The salient finding from our study is that simple opportunities 
to identify early cases of SARS- CoV-2 infection were missed due 
to overly stringent case- criteria. Had the diagnostic criteria been 
widened earlier to include patients with compatible symptoms 
but no travel history, it is likely that earlier imported infections 
would have been detected, enabling rapid deployment of infec-
tion control measures that may have prevented onwards trans-
mission. However, the diagnostic capacity available nationally 
was not sufficient at the time to process the volume of testing 
required with a broader case definition. This would have been 
ameliorated by increased local testing within PHE and NHS 
diagnostic laboratories earlier in the epidemic. Many of these 
laboratories possessed the knowledge and experience necessary 
to initiate local testing but were unable to do so due to a delayed 
mandate and the availability of commercial testing platforms, 
on which many diagnostic services rely. For future pandemic 
preparedness, the UK urgently needs to invest in and expand 
diagnostic capacity within NHS and PHE diagnostic laboratory 
services, ensuring the rapid dissemination of diagnostic proto-
cols, a stable supply chain of reagents and instruments required 
to sustain a rapid increase in capacity and provide a fully 
integrated end- to- end result system to ensure appropriate and 
timely infection prevention and control measures can be taken 
within secondary care and community settings. Any lasting 
investment in the human resources and associated infrastruc-
ture to achieve a more agile epidemic response both nationally 
and globally will undoubtedly save lives and drastically reduce 
the adverse impact of such outbreaks on the economy.
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